Acurx Pharmaceuticals Inc Stock Price, News & Analysis

Acurx Pharmaceuticals announced a warrant exercise agreement generating $2.67 million in gross proceeds. A holder of existing warrants for 4,445,435 shares with exercise prices of $3.25-$3.26 agreed to exercise them at a reduced price of $0.60 per share. In exchange, the holder received new warrants (G-1 and G-2) to purchase up to 8,890,870 shares at $0.425 per share. The G-1 Warrants (6,223,609 shares) are immediately exercisable, while G-2 Warrants (2,667,261 shares) require shareholder approval. Both new warrants expire in five years. The company plans to use proceeds for working capital and general corporate purposes. The new warrants are issued through private placement under Section 4(a)(2) of the Securities Act.

Acurx Pharmaceuticals (NASDAQ: ACXP) announced the publication of Phase 2b clinical trial results for ibezapolstat (IBZ) in Lancet Microbe, showing superior efficacy in treating C. difficile infection (CDI) compared to standard treatment. The trial demonstrated 94% clinical cure rate with IBZ, with 100% of cured patients remaining recurrence-free after one month, versus 14% recurrence rate with vancomycin. IBZ also showed favorable effects on gut microbiome preservation. The drug has received FDA QIDP and Fast-Track Designation, plus EMA SME status. The company is now positioned to advance to Phase 3 international trials, supported by comprehensive data including chemistry, mechanism of action, and microbiological activity. This development is particularly significant as current treatments show lower cure rates and emerging antimicrobial resistance issues.

Acurx Pharmaceuticals (NASDAQ: ACXP) presented results from its collaboration with Leiden University Medical Center (LUMC) regarding DNA pol IIIC inhibitors at the FASEB Scientific Conference. The research focused on ibezapolstat (IBZ), Acurx's lead antibiotic candidate, which is ready to enter Phase 3 clinical trials for C. difficile Infection (CDI). The study revealed a unique inhibitor conformation that selectively targets DNA Polymerase PolC in Gram-positive bacteria. Ibezapolstat has received FDA QIDP and Fast-Track Designations, along with EMA's SME designation. The research provides insights into the drug's mechanism of action and selectivity, supporting the development of new compounds to combat antimicrobial resistance.

Acurx Pharmaceuticals (NASDAQ: ACXP) reported its Q1 2025 financial results and business updates. The company raised $3.6 million through two registered direct offerings and secured a $12 million equity line of credit. Q1 financial highlights include a net loss of $2.1 million ($0.11 per share), improved from a $4.4 million loss year-over-year, with reduced R&D expenses of $0.6 million and G&A expenses of $1.6 million.

Key developments include positive EMA guidance for ibezapolstat's Phase 3 clinical trial program, aligned with FDA requirements. Two significant studies funded by NIAID demonstrated ibezapolstat's microbiome-restorative potential and favorable gut microbiome impact compared to other antibiotics. The company also secured new patents in Japan and India for DNA polymerase IIIC inhibitors, extending protection until December 2039.

Acurx Pharmaceuticals (NASDAQ: ACXP), a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, has scheduled its first quarter 2025 financial results conference call for May 13, 2025, at 8:00 am ET.

The conference call will be led by David P. Luci, President and CEO, and Robert G. Shawah, Chief Financial Officer. They will present the financial results and provide a business update before the U.S. markets open.

Interested participants can join the call using the following details:

• U.S. Toll-free: 1-877-790-1503
• Conference ID: 13753625
• International callers can access toll-free numbers via a dedicated website

Acurx Pharmaceuticals (Nasdaq: ACXP) has announced its participation in the Alliance Global Partners (A.G.P) Healthcare Company Showcase on May 21, 2025, at 9:00 a.m. ET. David P. Luci, President & CEO, will engage in a virtual fireside chat presentation.

The company, which specializes in developing small molecule antibiotics for difficult-to-treat bacterial infections, will showcase its lead antibiotic candidate ibezapolstat (IBZ). This drug is prepared to progress to international Phase 3 clinical trials for treating C. difficile infection (CDI).

The presentation will be available via live webcast, with a replay accessible through the News/Events section on the company's website at www.acurxpharma.com.

Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the Indian Patent Office in March 2025 for DNA Polymerase IIIC Inhibitors, including compositions-of-matter. This adds to their existing portfolio of three U.S. patents, one Israeli patent, and one Japanese patent, all covering the ACX-375C program.

The company's lead DNA pol IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile Infection. Their second-generation compounds are being developed for both oral and parenteral use to treat infections caused by gram-positive bacteria, including:

• Staphylococcus aureus (including MRSA)
• VRE and DRSP
• B. anthracis (anthrax), a Bioterrorism Category A Threat-Level pathogen

Acurx Pharmaceuticals (NASDAQ: ACXP) has reported its Q4 and full-year 2024 results. Key highlights include positive Phase 2b clinical trial results for ibezapolstat, showing a 96% clinical cure rate across combined Phase 2 trials, with 100% sustained cure rate through one month post-treatment, compared to 86% for vancomycin.

The company secured positive regulatory guidance from EMA for ibezapolstat's Phase 3 program, aligning with FDA requirements. Financial results show cash position of $3.7 million as of December 31, 2024, down from $7.5 million year-over-year. The company raised $6.6 million through ATM financing in 2024.

Q4 2024 showed reduced losses with net loss of $2.8 million ($0.16 per share) compared to $5.1 million ($0.37 per share) in Q4 2023. Full-year 2024 net loss was $14.1 million ($0.87 per share) versus $14.6 million ($1.15 per share) in 2023.

Acurx Pharmaceuticals (NASDAQ: ACXP) has announced the closing of a $1.1 million registered direct offering, consisting of 2,745,000 shares of common stock priced at $0.40 per share. The late-stage biopharmaceutical company, focused on developing new antibiotics for difficult-to-treat bacterial infections, also issued unregistered warrants in a concurrent private placement.

The warrants allow for the purchase of up to 8,235,000 shares at an exercise price of $0.40 per share, exercisable upon stockholder approval and expiring 24 months thereafter. H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.